Contreras-Gómez María José, Martinez José R W, Rivas Lina, Riquelme-Neira Roberto, Ugalde Juan A, Wozniak Aniela, García Patricia, Munita José M, Olivares-Pacheco Jorge, Alcalde-Rico Manuel
Grupo de Resistencia Antimicrobiana en Bacterias Patógenas y Ambientales (GRABPA), Instituto de Biología, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
Genomics and Resistant Microbes Group (GeRM), Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Clínica Alemana, Universidad Del Desarrollo, Santiago, Chile.
Front Pharmacol. 2022 Oct 3;13:1007162. doi: 10.3389/fphar.2022.1007162. eCollection 2022.
Carbapenem-resistant (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against are ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T). Although mechanisms leading to CZA and C/T resistance have already been described, among which are the resistance-nodulation-division (RND) efflux pumps, the role that these extrusion systems may play in CZA, and C/T baseline susceptibility of clinical isolates remains unknown. For this purpose, 161 isolates of non-carbapenemase-producing (Non-CP) CRPA were selected, and susceptibility tests to CZA and C/T were performed in the presence and absence of the RND efflux pumps inhibitor, Phenylalanine-arginine β-naphthylamide (PAβN). In the absence of PAβN, C/T showed markedly higher activity against Non-CP-CRPA isolates than observed for CZA. These results were even more evident in isolates classified as extremely-drug resistant (XDR) or with difficult-to-treat resistance (DTR), where CZA decreased its activity up to 55.2% and 20.0%, respectively, whereas C/T did it up to 82.8% (XDR), and 73.3% (DTR). The presence of PAβN showed an increase in both CZA (37.6%) and C/T (44.6%) activity, and 25.5% of Non-CP-CRPA isolates increased their susceptibility to these two combined antibiotics. However, statistical analysis showed that only the C/T susceptibility of Non-CP-CRPA isolates was significantly increased. Although the contribution of RND activity to CZA and C/T baseline susceptibility was generally low (two-fold decrease of minimal inhibitory concentrations [MIC]), a more evident contribution was observed in a non-minor proportion of the Non-CP-CRPA isolates affected by PAβN [CZA: 25.4% (15/59); C/T: 30% (21/70)]. These isolates presented significantly higher MIC values for C/T. Therefore, we conclude that RND efflux pumps are participating in the phenomenon of baseline susceptibility to CZA and, even more, to C/T. However, the genomic diversity of clinical isolates is so great that deeper analyzes are necessary to determine which elements are directly involved in this phenomenon.
耐碳青霉烯类(CRPA)是急需新型药物和新控制手段的病原体之一。对抗这种细菌的主要策略是将β-内酰胺类药物与β-内酰胺酶抑制剂联合使用。最常用的联合用药是头孢他啶/阿维巴坦(CZA)和头孢洛扎/他唑巴坦(C/T)。虽然导致对CZA和C/T耐药的机制已经被描述,其中包括耐药-结瘤-分裂(RND)外排泵,但这些外排系统在CZA和C/T耐药方面可能发挥的作用以及临床分离株对它们的基线敏感性仍然未知。为此,我们选择了161株非产碳青霉烯酶(Non-CP)的CRPA分离株,并在存在和不存在RND外排泵抑制剂苯丙氨酸-精氨酸β-萘酰胺(PAβN)的情况下,对CZA和C/T进行了药敏试验。在不存在PAβN的情况下,C/T对Non-CP-CRPA分离株的活性明显高于CZA。这些结果在被归类为广泛耐药(XDR)或难治性耐药(DTR)的分离株中更为明显,其中CZA的活性分别降低了55.2%和20.0%,而C/T分别降低了82.8%(XDR)和73.3%(DTR)。PAβN的存在使CZA(37.6%)和C/T(44.6%)的活性均有所增加,并且25.5%的Non-CP-CRPA分离株对这两种联合抗生素的敏感性增加。然而,统计分析表明,只有Non-CP-CRPA分离株对C/T的敏感性显著增加。虽然RND活性对CZA和C/T基线敏感性的贡献通常较低(最低抑菌浓度[MIC]降低两倍),但在受PAβN影响的非少数比例的Non-CP-CRPA分离株中观察到了更明显的贡献[CZA:25.4%(15/59);C/T:30%(21/70)]。这些分离株对C/T的MIC值显著更高。因此,我们得出结论,RND外排泵参与了对CZA,甚至更重要的是对C/T的基线敏感性现象。然而,临床分离株的基因组多样性非常大,需要更深入的分析来确定哪些因素直接参与了这一现象。